Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, December 10, 2013 LONDON, December 10, 2013 /PRNewswire/ -- On Monday, December 09, 2013, the U.S. equity market advanced. The S&P 500 ended the day at 1,808.37, up 0.18%; the Dow Jones Industrial Average closing at 16,025.53, up 0.03%; and the NASDAQ Composite finishing at 4,068.75, up 0.15%. The S&P 500 Health Care Sector Index gained 0.19% to close at 638.95; and the S&P 500 Pharmaceuticals Sub Industry Index closed 0.14% higher at 490.41. The S&P 500 Pharmaceuticals Sub Industry Index has advanced 2.42% in the previous one month and 10.03% in the last three months, outperforming the S&P 500, which has gained 2.13% and 8.17% during the respective periods. The major movers in the industry included Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). AAAResearchReports.com free coverage on PFE, MRK, ABBV, and ZGNX is available upon registration at: http://www.aaaresearchreports.com/register/ Pfizer Inc.'s stock edged 0.13% higher on Monday, finishing the day at $31.58, after fluctuating between $31.41 and $31.69 during the trading session. A total of 21.13 million shares were traded, which is below the daily average volume of 25.27 million. The company's shares have gained 0.99% in the previous three trading sessions and 11.59% in the last three months, outperforming the S&P 500, which has gained 0.87% and 8.17% during the respective periods. Moreover, Pfizer Inc.'s stock is trading above its 50-day and 200-day moving averages of $30.63 and $29.22, respectively. Download free technical research on PFE by signing up at: http://www.AAAResearchReports.com/PFE121013.pdf Merck & Co. Inc.'s stock advanced 0.34% on Monday, tracking gains in the US equity market. The company's shares closed the day at $49.56, after oscillating between $49.20 and $49.85 during the trading session. A total of 9.28 million shares were traded, which is below the daily average volume of 14.33 million. The company's shares have advanced 5.90% in the previous one month, outperforming the S&P 500, which has advanced 2.13% during the same period. Furthermore, Merck & Co. Inc.'s stock is trading above its 50-day and 200-day moving averages of $47.51 and $46.92, respectively. Register now and get access to free analysis on MRK at: http://www.AAAResearchReports.com/MRK121013.pdf Shares in AbbVie Inc. hit a new 52-week high of $51.81 on Monday, before declining 0.27% to close the day at $51.21. The company's shares vacillated between $50.77 and $51.81 during the trading session. A total of 5.44 million shares were traded, which is above the daily average volume of 4.99 million. Despite Monday's decline, the company's shares have gained 15.26% in the previous three months and 6.62% in the last one month, outperforming the S&P 500, which has gained 8.17% and 2.13% during the respective periods. Moreover, AbbVie Inc.'s stock is trading above its 50-day and 200-day moving averages of $47.82 and $44.27, respectively. Sign up and read our complimentary report on ABBV at: http://www.AAAResearchReports.com/ABBV121013.pdf Zogenix Inc.'s stock plummeted 4.00% on Monday, closing at $3.12, after fluctuating between $3.01 and $3.27 during the trading session. A total of 1.65 million shares were traded, which is below the daily average volume of 1.89 million. Despite Monday's pullback, the company's shares have surged 17.29% in the last one month and 65.96% in the previous three months, outperforming the S&P 500, which has advanced 2.13% and 8.17% during the respective periods. Further, Zogenix Inc.'s stock is trading above its 50-day and 200-day moving averages of $2.64 and $1.91, respectively. The free report on ZGNX can be downloaded by signing up now at: http://www.AAAResearchReports.com/ZGNX121013.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org
Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix
Press spacebar to pause and continue. Press esc to stop.